Palliative treatment for advanced non-small cell lung cancer

It should go without saying that all patients with advanced NSCLC are entitled to the treatment and care described in this article. It is probably also true that in many countries where these patients are often elderly and socially disadvantaged, they may have very variable access to this treatment and care. There is reasonable research evidence that both chemotherapy and palliative radiotherapy are modestly effective in controlling symptoms and prolonging life for some patients, but with significant risks of unpleasant and sometimes life-threatening toxicity. For this large and important group of patients, however, there are a large number of unanswered questions about the best regimens to use, how best to select patients so that they get the greatest benefit, how to mitigate side effects, and how best to integrate all the available treatment options. There have been significantly more trials in chemotherapy, but we must not overlook the need for research into palliative radiotherapy and other supportive care measures. There is still plenty of scope for intelligent and coordinated research.